Literature DB >> 10813234

Molecular biology of lung cancer.

G Sozzi1, D Carney.   

Abstract

Lung cancer is a major cause of mortality worldwide and the overall survival rate has not improved significantly in the past 20 years. Of the more than 150,000 new cases of lung cancer diagnosed in Europe every year, less than 10% of patients can be cured and enjoy long-term survival. The role of tobacco smoking as a cause of lung cancer has been conclusively established. Early diagnosis of lung cancer, based on conventional screening procedures using sputum cytology and chest radiography, has been so far unable to decrease lung cancer mortality. We discuss here the possibility that novel, more specific molecular markers, beside providing new understanding of the process of lung carcinogenesis, may also constitute new tools for early diagnosis allowing for screening of high-risk individuals, determination of prognosis, and identification of innovative treatments.

Entities:  

Mesh:

Year:  1998        PMID: 10813234     DOI: 10.1097/00063198-199807000-00004

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  5 in total

1.  Bioinformatics analysis and expression study of fumarate hydratase in lung cancer.

Authors:  Zongjuan Ming; Meihua Jiang; Wei Li; Na Fan; Wenjing Deng; Yujie Zhong; Yuping Zhang; Qiuhong Zhang; Shuanying Yang
Journal:  Thorac Cancer       Date:  2014-10-23       Impact factor: 3.500

2.  Bioinformatics analysis of Rab GDP dissociation inhibitor beta and its expression in non-small cell lung cancer.

Authors:  Zongjuan Ming; Chunli Guo; Meihua Jiang; Wei Li; Yuping Zhang; Na Fan; Yujie Zhong; Xia Meng; Shuanying Yang
Journal:  Diagn Pathol       Date:  2014-11-04       Impact factor: 2.644

3.  Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.

Authors:  Rui Chen; Xiaoming Hou; Liping Yang; Da Zhao
Journal:  Thorac Cancer       Date:  2019-02-07       Impact factor: 3.500

4.  Expression of NDRG2 in human lung cancer and its correlation with prognosis.

Authors:  Shu-Jun Li; Wen-Yong Wang; Bing Li; Bei Chen; Bo Zhang; Xin Wang; Chang-Sheng Chen; Qing-Chuan Zhao; Hai Shi; Libo Yao
Journal:  Med Oncol       Date:  2013-01-10       Impact factor: 3.064

5.  Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review.

Authors:  Bum Jun Kim; Jung Han Kim; Hyeong Su Kim
Journal:  Oncotarget       Date:  2017-04-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.